Evidence map›Paper›PMID 33138150›Full record

ArticleCells2020

Overexpression of α-Synuclein by Oligodendrocytes in Transgenic Mice Does Not Recapitulate the Fibrillar Aggregation Seen in Multiple System Atrophy.

Florent Laferrière, Xin He, Federica Zinghirino, Evelyne Doudnikoff, Emilie Faggiani, Wassilios G Meissner, Erwan Bezard, Francesca De Giorgi, François Ichas

Open access · goldAbstract read
In one paragraph

Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Monitoring α-synuclein aggregation.Neurobiology of disease · 2023
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 3 countries.

Florent LaferrièreCNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.ORCID 0000-0002-0753-5505
Xin HeCNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.
Federica ZinghirinoCNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.ORCID 0000-0001-8822-4217
Evelyne DoudnikoffCNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.
Emilie FaggianiCNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.
Wassilios G MeissnerCNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.
Erwan BezardCNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.ORCID 0000-0002-0410-4638
Francesca De GiorgiCNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.
François IchasCNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.ORCID 0000-0001-8184-5248
Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The synucleinopathy underlying multiple system atrophy (MSA) is characterized by the presence of abundant amyloid inclusions containing fibrillar α-synuclein (α-syn) aggregates in the brains of the patients and is associated with an extensive neurodegeneration. In contrast to Parkinson's disease (PD) where the pathological α-syn aggregates are almost exclusively neuronal, the α-syn inclusions in MSA are principally observed in oligodendrocytes (OLs) where they form glial cytoplasmic inclusions (GCIs). This is intriguing because differentiated OLs express low levels of α-syn, yet pathogenic amyloid α-syn seeds require significant amounts of α-syn monomers to feed their fibrillar growth and to eventually cause the buildup of cytopathological inclusions. One of the transgenic mouse models of this disease is based on the targeted overexpression of human α-syn in OLs using the PLP promoter. In these mice, the histopathological images showing a rapid emergence of S129-phosphorylated α-syn inside OLs are considered as equivalent to GCIs. Instead, we report here that they correspond to the accumulation of phosphorylated α-syn monomers/oligomers and not to the appearance of the distinctive fibrillar α-syn aggregates that are present in the brains of MSA or PD patients. In spite of a propensity to co-sediment with myelin sheath contaminants, the phosphorylated forms found in the brains of the transgenic animals are soluble (>80%). In clear contrast, the phosphorylated species present in the brains of MSA and PD patients are insoluble fibrils (>95%). Using primary cultures of OLs from PLP-αSyn mice we observed a variable association of S129-phosphorylated α-syn with the cytoplasmic compartment, the nucleus and with membrane domains suggesting that OLs functionally accommodate the phospho-α-syn deriving from experimental overexpression. Yet and while not taking place spontaneously, fibrillization can be seeded in these primary cultures by challenging the OLs with α-syn preformed fibrils (PFFs). This indicates that a targeted overexpression of α-syn does not model GCIs in mice but that it can provide a basis for seeding aggregation using PFFs. This approach could help establishing a link between α-syn aggregation and the development of a clinical phenotype in these transgenic animals.

Indexed as

Protein Aggregatesalpha-SynucleinAmyloidAnimalsBrainCells, CulturedHumansMice, Inbred C57BLMice, TransgenicModels, AnimalMultiple System AtrophyMyelin Basic ProteinMyelin Proteolipid ProteinNeuronsOligodendrogliaParkinson Diseasealpha-SynucleinAmyloidMyelin Basic ProteinMyelin Proteolipid ProteinPhosphoserineProtein AggregatesGCIsmultiple system atrophyα-synuclein

Identifiers

PMID33138150
PMCPMC7693764
OpenAlexW3096545518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.